How AI is Transforming Health Care at AdventHealth

Side by side headshots of Dr. Victor Herrera and Rob Purinton
Dr. Victor Herrera, senior vice president and chief clinical officer, AdventHealth Central Florida (left) and Rob Purinton, vice president of clinical analytics and performance improvement at AdventHealth (right)

“Artificial intelligence is now providing tools that allow us to be more efficient and effective when taking care of patients and we can do it in a way that is safer,” says Dr. Victor Herrera, senior vice president and chief clinical officer for AdventHealth Central Florida.

In this episode of the Inspiring Wholeness podcast, Herrera and Rob Purinton, vice president of clinical analytics and performance improvement at AdventHealth, talk AI – both predictive and generative – and how these new technologies benefit patients and providers.

According to Purinton, at AdventHealth, they’re looking at the idea of augmented intelligence, not just artificial intelligence. He says, “How does AI help make our clinicians work smarter, not harder? How does it augment them?”

Listen now and subscribe so you never miss a new episode.

Recent News

12 items. To interact with these items, press Control-Option-Shift-Right Arrow. These items are in a slider. To advance slider forward, press Shift-Command-Right Arrow. To advance slider backward, press Shift-Command-Left Arrow.
News
AdventHealth Celebration Successfully Performs First Robotics-assisted Cochlear Implant Procedure in Florida with the iotaSOFT® Insertion System.

In January 2024, AdventHealth Celebration neurotologist Michael Seidman, MD, FACS, became the first in Florida and the Southeast to complete a robotics-assisted cochlear implant procedure using the...

Read Article about "AdventHealth Celebration Successfully Performs First Robotics-assisted Cochlear Implant Procedure in Florida with the iotaSOFT® Insertion System."
News
New England Journal of Medicine highlights Guru Sonpavde, MD’s work in new immunotherapy-chemotherapy combination improving survival for patients with advanced urothelial carcinoma

The CheckMate 901 Phase III clinical trial results, recently published in the New England Journal of Medicine, found that combining the programmed death 1 (PD1) inhibitor immunotherapy nivolumab with...

Read Article about "New England Journal of Medicine highlights Guru Sonpavde, MD’s work in new immunotherapy-chemotherapy combination improving survival for patients with advanced urothelial carcinoma"
View More Articles